ArticleFrontiers in immunology2026
Decoding the landscape of bispecific antibodies in breast cancer: insights from a comprehensive trial analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bispecific antibodies (bsAbs) represent a novel therapeutic strategy for breast cancer by leveraging diverse mechanisms of action (MOA) to overcome the limitations of conventional therapies. However, systematic analyses of bsAbs in breast cancer remain scarce. Based on the Trialtrove database (search up to September 7, 2025), we identified 193 eligible clinical trials investigating bsAbs in breast cancer. Our analysis reveals a significant surge in trials beginning in 2019, peaking in 2023. While most trials are in early phases (73.58%), the emergence of Phase III studies since 2023 signals a maturation trend. Immune checkpoint modulation dominates (64.77%), with PD-1/PD-L1 blockade as the leading strategy, followed by HER2-targeting bsAbs. Completed trials with positive outcomes highlight PD-1-based and HER2-targeted bsAbs as the most promising candidates. These findings provide a data-driven roadmap for bsAbs development in breast cancer, emphasizing the need to optimize target combinations and identify predictive biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.